AUTH/3630/4/22 - Ex-employee v Daiichi Sankyo

Mobile view of Daiichi Sankyo website promoting Lixiana

  • Case number
    AUTH/3630/4/22
  • Complaint received
    11 April 2022
  • Completed
    15 March 2023
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions

Case Summary

This case was in relation to the homepage of Daiichi Sankyo’s promotional Lixiana (edoxaban) mobile website which included the prescribing information and adverse event reporting statement within a collapsible menu bar.

The Panel ruled a breach of the following Clause(s) of the 2021 Code:

Breach of Clause 12.1

Not meeting the requirement for prescribing information to be positioned for ease of reference

Breach of Clause 12.4

Failing to provide prescribing information by way of a clear, and prominent, direct, single click link

Breach of Clause 12.6

Failing to include a clear prominent statement as to where the prescribing information can be found

Breach of Clause 12.9

Failing to include the adverse event reporting statement in a prominent manner

Breach of Clause 5.1

Failing to maintain high standards

The Panel ruled no breach of the following Clause(s) of the 2021 Code:

No Breach of Clause 12.1

The requirement, amongst other things, for prescribing information to be provided in a clear and legible manner

No Breach of Clause 2

Requirement that activities or material must not bring discredit upon, or reduce confidence in, the pharmaceutical industry


This summary is not intended to be read in isolation.
For full details, please see the full case report